ID   ME-F2/ADM100
AC   CVCL_G315
DR   cancercelllines; CVCL_G315
DR   Wikidata; Q54904907
RX   PubMed=9177449;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_G313 ! ME-F2
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 15
//
RX   PubMed=9177449; DOI=10.1038/sj.leu.2400663;
RA   Utsunomiya Y., Hasegawa H., Yanagisawa K., Fujita S.;
RT   "Enhancement of mdr1 gene expression by transforming growth factor-beta1
RT   in the new adriamycin-resistant human leukemia cell line ME-F2/ADM.";
RL   Leukemia 11:894-895(1997).
//